Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of short-term renal hemodynamic effects of oral tolvaptan in ADPKD
2010-019025-33Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Measured glomerular filtration rate, Renal plasma flow and 3 more. Started Jul 2010; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2010-019025-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019025-33.